Risks
4 risks
Risk Intelligence
US business uncertainty and pricing erosion
View Risks →
Glenmark Pharmaceuticals Limited — Q2 FY24
Glenmark's Q2 FY24 consolidated revenue grew 6.3% YoY to INR 3,588 crore, driven by strong performance in Europe (+58.4%) and ROW (+19%), while India grew only 2.8% due to acute segment slowdown and US declined 1.9% due to supply disruptions.
neutral
medium
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Glenmark's Q2 FY24 consolidated revenue grew 6.3% YoY to INR 3,588 crore, driven by strong performance in Europe (+58.4%) and ROW (+19%), while India grew only 2.8% due to acute segment slowdown and US declined 1.9% due to supply disruptions. EBITDA margin (ex-forex) was 15.7%, impacted by remediation costs and lower US/India sales. Management guided for core EBITDA margins to reach ~19% by FY25, aided by 2% improvement from lower R&D spend and operating leverage in Europe/LatAm. The GLS divestment (75% stake to Nirma) is expected to close in Q3, significantly improving PAT margins. Key risks include US business uncertainty, Monroe facility reinspection timeline, and pricing erosion in the US generics market.
ग्लेनमार्क की दूसरी तिमाही में कुल कमाई पिछले साल से 6.3% बढ़कर 3,588 करोड़ रुपये हो गई। यूरोप में 58.4% और बाकी देशों में 19% की मजबूत बढ़त रही, जबकि भारत में सिर्फ 2.8% बढ़ोतरी हुई और अमेरिका में आपूर्ति में रुकावट के कारण 1.9% गिरावट आई। कंपनी का मुनाफा मार्जिन 15.7% रहा, जो मरम्मत खर्च और कम बिक्री से प्रभावित हुआ। प्रबंधन का अनुमान है कि अगले साल तक मुख्य मार्जिन लगभग 19% तक पहुंच जाएगा, क्योंकि रिसर्च खर्च घटेगा और यूरोप-लैटिन अमेरिका में बिक्री बढ़ेगी। ग्लेनमार्क अपनी जीएलएस इकाई का 75% हिस्सा निर्मा को बेच रहा है, जिससे मुनाफा काफी बढ़ेगा। जोखिमों में अमेरिकी कारोबार की अनिश्चितता और जेनेरिक दवाओं की कीमतों में गिरावट शामिल है।
Risks4 trackedTranscriptfull text
Research workspace
Focused Modules
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
India Formulation Growth (Q2)
2.8%
+2.8% YoY
India formulation sales grew 2.8% YoY to INR 11,217 million, impacted by acute segment slowdown and NLEM price revisions.
Europe Revenue Growth (Q2)
58.4%
+58.4% YoY
Europe revenue surged 58.4% YoY to INR 5,997 million, driven by strong branded and generics business, especially in UK and CEE.
US Revenue (Q2)
$89.4M
-5.9% YoY
US revenue declined to $89.4 million due to supply disruptions from remediation; management expects recovery in Q3 with new launches.
Ryaltris Market Launches
29 markets
+29 markets cumulative
Ryaltris commercialized in 29 markets; applications submitted in over 70 markets, with strong uptake in Europe, Asia, and Middle East.
What Changed vs Last Quarter
NEW
Core EBITDA margin target of ~19% by FY25
Management expects core EBITDA margins to reach ~19% in FY25, driven by 2% improvement from lower R&D spend and additional operating leverage from Europe and LatAm.
NEW
India business to grow 12-15% over next 3 years
India formulation business expected to grow at 12-15% CAGR over the next three years, supported by Rx, OTC, and institutional segments.
NEW
Fluticasone MDI filing by Q4 FY24/Q1 FY25
Glenmark expects to file the fluticasone MDI (generic Flonase) in the US by end of FY24 or early FY25.
UPDATED
Europe business to grow 15-20% minimum
Europe business expected to grow at a minimum of 15-20% going forward, driven by respiratory portfolio and Ryaltris.
DROPPED
Consolidated revenue growth of 10-11% for FY24
Management expects full-year revenue growth of 10-11%, with potential to exceed guidance.
DROPPED
Consolidated EBITDA margin of 19-20%+ for FY24
EBITDA margin target of 19-20%+ for the full year, with Q1 at 18.6% (19% ex-forex).
DROPPED
CapEx of INR 600-700 crore for FY24
Consolidated capital expenditure guided at INR 600-700 crore for the full year.
NEW RISK
US business uncertainty and pricing erosion
US business remains a big unknown due to pricing erosion (~5% mid-single digit) and supply disruptions; management struggles to provide specific guidance.
NEW RISK
Monroe facility reinspection timeline uncertain
Monroe facility remediation is largely complete, but FDA reinspection timeline is unpredictable, delaying potential revenue from the plant.
NEW RISK
GLS divestment execution risk
The GLS divestment to Nirma is subject to regulatory and shareholder approvals; any delay could impact FY25 margin and PAT improvement plans.
RISK GONE
USFDA warning letter for Monroe plant
Monroe facility received a warning letter, potentially delaying injectable product approvals and US growth acceleration.
RISK GONE
Debt and interest cost increase
Net debt at INR 2,947 crore and interest costs doubled YoY due to higher LIBOR, impacting profitability.
RISK GONE
Glenmark Life Sciences stake sale uncertainty
Mandatory 7-8% stake sale in GLS by August 2024 may not significantly reduce debt as expected by some analysts.
Fast read
Guidance and risk preview
Management expects core EBITDA margins to reach ~19% in FY25, driven by 2% improvement from lower R&D spend and additional operating leverage from...
US business remains a big unknown due to pricing erosion (~5% mid-single digit) and supply disruptions; management struggles to provide specific gu...
View Risks →